Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00394693
Status:
COMPLETED
Last Update Posted:
2014-07-16
First Post:
2006-10-31
Brief Title:
Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma
Sponsor:
Transgene
Organization:
Transgene
Study Overview
Official Title:
Phase II Clinical Trial of Intra-lesional Administration of TG1042 Adenovirus-Interferon-gamma in Patients With Relapsing Primary Cutaneous B-Cell Lymphomas
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to evaluate the efficacy of a four-month dosing period of intra-lesional injection of TG1042 in patients with relapsing CBCL
Patients will receive intra-tumoral injections of an adenoviral vector construct containing the human interferon gamma gene TG1042 in an attempt to enhance immune responses with anti-tumor activity This local administration induces tumour cell killing at the injected tumour sites
Patients will receive intra-tumoral injections of an adenoviral vector construct containing the human interferon gamma gene TG1042 in an attempt to enhance immune responses with anti-tumor activity This local administration induces tumour cell killing at the injected tumour sites
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None